{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:11:11Z","timestamp":1771474271695,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R21EY027065"],"award-info":[{"award-number":["R21EY027065"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R41EY027665"],"award-info":[{"award-number":["R41EY027665"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY027749-01A1"],"award-info":[{"award-number":["R01EY027749-01A1"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"crossref","award":["1-18-IBS-172"],"award-info":[{"award-number":["1-18-IBS-172"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"crossref","award":["Special Scholar Award"],"award-info":[{"award-number":["Special Scholar Award"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarships Council","doi-asserted-by":"crossref","award":["[2016] 3100"],"award-info":[{"award-number":["[2016] 3100"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["14PRE18310014"],"award-info":[{"award-number":["14PRE18310014"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16PRE27250308"],"award-info":[{"award-number":["16PRE27250308"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10456-019-09662-4","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T11:58:54Z","timestamp":1547467134000},"page":"369-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety"],"prefix":"10.1007","volume":"22","author":[{"given":"Fen","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle E.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Han","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8764","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"issue":"8","key":"9662_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465\u2013477. https:\/\/doi.org\/10.1038\/nrclinonc.2009.94","journal-title":"Nat Rev Clin Oncol"},{"issue":"9902","key":"9662_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstrom","year":"2013","unstructured":"Hellstrom A, Smith LE, Dammann O (2013) Retinopathy of prematurity. Lancet 382(9902):1445\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(13)60178-6","journal-title":"Lancet"},{"key":"9662_CR3","unstructured":"National Eye Institute. Facts about retinopathy of prematurity (ROP). at https:\/\/nei.nih.gov\/health\/rop\/rop"},{"issue":"2","key":"9662_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/08820530902800322","volume":"24","author":"IS Mantagos","year":"2009","unstructured":"Mantagos IS, Vanderveen DK, Smith LE (2009) Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 24(2):82\u201386. https:\/\/doi.org\/10.1080\/08820530902800322","journal-title":"Semin Ophthalmol"},{"key":"9662_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_78","volume":"242","author":"YM Paulus","year":"2017","unstructured":"Paulus YM, Sodhi A (2017) Anti-angiogenic therapy for retinal disease. Handb Exp Pharmacol 242:271\u2013307. https:\/\/doi.org\/10.1007\/164_2016_78","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"9662_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M et al (2017) Comparison of intravitreal injection of ranibizumab versus laser therapy for zone Ii treatment-requiring retinopathy of prematurity. Retina 37(4):710\u2013717. https:\/\/doi.org\/10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"issue":"7","key":"9662_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"9","key":"9662_CR8","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123(9):1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"issue":"11","key":"9662_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121(11):2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","journal-title":"Ophthalmology"},{"issue":"5","key":"9662_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","volume":"14","author":"SY Jang","year":"2010","unstructured":"Jang SY, Choi KS, Lee SJ (2010) Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J Am Assoc Pediatr Opthalmol Strabismus 14(5):457\u2013459. https:\/\/doi.org\/10.1016\/j.jaapos.2010.05.011","journal-title":"J Am Assoc Pediatr Opthalmol Strabismus"},{"issue":"3","key":"9662_CR11","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1167\/iovs.13-13397","volume":"55","author":"CC Tokunaga","year":"2014","unstructured":"Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E et al (2014) Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 55(3):1884\u20131892. https:\/\/doi.org\/10.1167\/iovs.13-13397","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"9662_CR12","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1167\/iovs.10-6798","volume":"52","author":"GA Lutty","year":"2011","unstructured":"Lutty GA, McLeod DS, Bhutto I, Wiegand SJ (2011) Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 52(7):4039\u20134047. https:\/\/doi.org\/10.1167\/iovs.10-6798","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"9662_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1084\/jem.20161802","volume":"214","author":"ME LeBlanc","year":"2017","unstructured":"LeBlanc ME, Wang W, Chen X, Caberoy NB, Guo F, Shen C et al (2017) Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med 214(4):1029\u20131047. https:\/\/doi.org\/10.1084\/jem.20161802","journal-title":"J Exp Med"},{"key":"9662_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/EB.S94447","volume":"8","author":"CB Kim","year":"2016","unstructured":"Kim CB, D\u2019Amore PA, Connor KM (2016) Revisiting the mouse model of oxygen-induced retinopathy. Eye Brain 8:67\u201379. https:\/\/doi.org\/10.2147\/EB.S94447","journal-title":"Eye Brain"},{"issue":"1\u20132","key":"9662_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0022-1759(99)00184-2","volume":"233","author":"Z Wang","year":"2000","unstructured":"Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R et al (2000) Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3\u2032 to 5\u2032 exonuclease activity. J Immunol Methods 233(1\u20132):167\u2013177","journal-title":"J Immunol Methods"},{"issue":"1","key":"9662_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clim.2010.09.008","volume":"138","author":"Y Kim","year":"2011","unstructured":"Kim Y, Caberoy NB, Alvarado G, Davis JL, Feuer WJ, Li W (2011) Identification of Hnrph3 as an autoantigen for acute anterior uveitis. Clin Immunol 138(1):60\u201366","journal-title":"Clin Immunol"},{"issue":"3","key":"9662_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ilar.46.3.269","volume":"46","author":"M Leenaars","year":"2005","unstructured":"Leenaars M, Hendriksen CF (2005) Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. Ilar J 46(3):269\u2013279","journal-title":"Ilar J"},{"issue":"3","key":"9662_CR18","doi-asserted-by":"publisher","first-page":"e92451","DOI":"10.1371\/journal.pone.0092451","volume":"9","author":"YN Abdiche","year":"2014","unstructured":"Abdiche YN, Miles A, Eckman J, Foletti D, Van Blarcom TJ, Yeung YA et al (2014) High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity. PLoS ONE 9(3):e92451. https:\/\/doi.org\/10.1371\/journal.pone.0092451","journal-title":"PLoS ONE"},{"issue":"2","key":"9662_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4161\/mabs.23049","volume":"5","author":"P Estep","year":"2013","unstructured":"Estep P, Reid F, Nauman C, Liu Y, Sun T, Sun J et al (2013) High throughput solution-based measurement of antibody-antigen affinity and epitope binning. mAbs 5(2):270\u2013278. https:\/\/doi.org\/10.4161\/mabs.23049","journal-title":"mAbs"},{"issue":"18","key":"9662_CR20","doi-asserted-by":"publisher","first-page":"7978","DOI":"10.1073\/pnas.88.18.7978","volume":"88","author":"CF Barbas","year":"1991","unstructured":"Barbas CF, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 88(18):7978\u20137982","journal-title":"Proc Natl Acad Sci USA"},{"key":"9662_CR21","volume-title":"Phage display: a laboratory manual","author":"CF Barbas","year":"2000","unstructured":"Barbas CF, Burton DR, Scott JK, Silverman GJ (2000) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor"},{"issue":"1\u20132","key":"9662_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1570-9639(02)00402-8","volume":"1599","author":"W Li","year":"2002","unstructured":"Li W, Handschumacher RE (2002) Identification of two calcineurin B-binding proteins: tubulin and heat shock protein 60. Biochim Biophys Acta 1599(1\u20132):72\u201381","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"9662_CR23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmr.983","volume":"23","author":"NB Caberoy","year":"2010","unstructured":"Caberoy NB, Zhou Y, Jiang X, Alvarado G, Li W (2010) Efficient identification of tubby-binding proteins by an improved system of T7 phage display. J Mol Recognit 23(1):74\u201383","journal-title":"J Mol Recognit"},{"issue":"11","key":"9662_CR24","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/nprot.2009.187","volume":"4","author":"KM Connor","year":"2009","unstructured":"Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI et al (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 4(11):1565\u20131573. https:\/\/doi.org\/10.1038\/nprot.2009.187","journal-title":"Nat Protoc"},{"issue":"1","key":"9662_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0016-5085(98)70368-3","volume":"115","author":"W Li","year":"1998","unstructured":"Li W, Krasinski SD, Verhave M, Montgomery RK, Grand RJ (1998) Three distinct messenger RNA distribution patterns in human jejunal enterocytes. Gastroenterology 115(1):86\u201392","journal-title":"Gastroenterology"},{"issue":"8","key":"9662_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/0748233709346755","volume":"25","author":"M Kurus","year":"2009","unstructured":"Kurus M, Ugras M, Esrefoglu M (2009) Effect of resveratrol on tubular damage and interstitial fibrosis in kidneys of rats exposed to cigarette smoke. Toxicol Ind Health 25(8):539\u2013544. https:\/\/doi.org\/10.1177\/0748233709346755","journal-title":"Toxicol Ind Health"},{"issue":"2","key":"9662_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.toxlet.2012.06.009","volume":"213","author":"M Toledo-Rodriguez","year":"2012","unstructured":"Toledo-Rodriguez M, Loyse N, Bourdon C, Arab S, Pausova Z (2012) Effect of prenatal exposure to nicotine on kidney glomerular mass and AT1R expression in genetically diverse strains of rats. Toxicol Lett 213(2):228\u2013234. https:\/\/doi.org\/10.1016\/j.toxlet.2012.06.009","journal-title":"Toxicol Lett"},{"issue":"11","key":"9662_CR28","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2012-04-396846","volume":"120","author":"P Sapieha","year":"2012","unstructured":"Sapieha P (2012) Eyeing central neurons in vascular growth and reparative angiogenesis. Blood 120(11):2182\u20132194. https:\/\/doi.org\/10.1182\/blood-2012-04-396846","journal-title":"Blood"},{"issue":"6573","key":"9662_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380(6573):439\u2013442. https:\/\/doi.org\/10.1038\/380439a0","journal-title":"Nature"},{"issue":"2","key":"9662_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/j.1460-2075.1990.tb08123.x","volume":"9","author":"DM Kingsley","year":"1990","unstructured":"Kingsley DM, Rinchik EM, Russell LB, Ottiger HP, Sutcliffe JG, Copeland NG et al (1990) Genetic ablation of a mouse gene expressed specifically in brain. EMBO J 9(2):395\u2013399","journal-title":"EMBO J"},{"issue":"4","key":"9662_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN et al (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133(4):391\u2013397. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5373","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"9662_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327 \u2013 33 e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"9662_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjophthalmol-2016-308828","volume":"101","author":"Y Kandasamy","year":"2017","unstructured":"Kandasamy Y, Hartley L, Rudd D, Smith R (2017) The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol 101(1):21\u201324. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308828","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"9662_CR34","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE (2013) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98(2):F170\u2013F174. https:\/\/doi.org\/10.1136\/archdischild-2011-301148","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"10","key":"9662_CR35","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/sj.ki.5000314","volume":"69","author":"S McGrath-Morrow","year":"2006","unstructured":"McGrath-Morrow S, Cho C, Molls R, Burne-Taney M, Haas M, Hicklin DJ et al (2006) VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney Int 69(10):1741\u20131748. https:\/\/doi.org\/10.1038\/sj.ki.5000314","journal-title":"Kidney Int"},{"issue":"35","key":"9662_CR36","doi-asserted-by":"publisher","first-page":"11036","DOI":"10.1523\/JNEUROSCI.23-35-11036.2003","volume":"23","author":"JM Rosenstein","year":"2003","unstructured":"Rosenstein JM, Mani N, Khaibullina A, Krum JM (2003) Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 23(35):11036\u201311044","journal-title":"J Neurosci"},{"issue":"7","key":"9662_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/jp.2009.166","volume":"30","author":"LO Atchaneeyasakul","year":"2010","unstructured":"Atchaneeyasakul LO, Trinavarat A (2010) Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 30(7):497\u2013499. https:\/\/doi.org\/10.1038\/jp.2009.166","journal-title":"J Perinatol"},{"issue":"1","key":"9662_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology 118(1):176\u2013183. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.018","journal-title":"Ophthalmology"},{"key":"9662_CR39","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3928\/01913913-20100901-04","volume":"47","author":"KK Suk","year":"2010","unstructured":"Suk KK, Berrocal AM, Murray TG, Rich R, Major JC, Hess D et al (2010) Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 47 Online:e1\u2013e4. https:\/\/doi.org\/10.3928\/01913913-20101217-06","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"11","key":"9662_CR40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"9662_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","volume":"22","author":"R Autrata","year":"2012","unstructured":"Autrata R, Krejcirova I, Senkova K, Holousova M, Dolezel Z, Borek I (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687\u2013694. https:\/\/doi.org\/10.5301\/ejo.5000166","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"9662_CR42","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1172\/JCI83427","volume":"126","author":"TA Al-Hilal","year":"2016","unstructured":"Al-Hilal TA, Chung SW, Choi JU, Alam F, Park J, Kim SW et al (2016) Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest 126(4):1251\u20131266. https:\/\/doi.org\/10.1172\/JCI83427","journal-title":"J Clin Invest"},{"issue":"7252","key":"9662_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature08151","volume":"460","author":"A Takeda","year":"2009","unstructured":"Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K et al (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460(7252):225\u2013230. https:\/\/doi.org\/10.1038\/nature08151","journal-title":"Nature"},{"issue":"2","key":"9662_CR44","doi-asserted-by":"publisher","first-page":"e17106","DOI":"10.1371\/journal.pone.0017106","volume":"6","author":"Y Li","year":"2011","unstructured":"Li Y, Huang D, Xia X, Wang Z, Luo L, Wen R (2011) CCR3 and choroidal neovascularization. PLoS ONE 6(2):e17106. https:\/\/doi.org\/10.1371\/journal.pone.0017106","journal-title":"PLoS ONE"},{"issue":"9","key":"9662_CR45","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1523\/JNEUROSCI.10-09-03135.1990","volume":"10","author":"HP Ottiger","year":"1990","unstructured":"Ottiger HP, Battenberg EF, Tsou AP, Bloom FE, Sutcliffe JG (1990) 1B1075: a brain- and pituitary-specific mRNA that encodes a novel chromogranin\/secretogranin-like component of intracellular vesicles. J Neurosci 10(9):3135\u20133147","journal-title":"J Neurosci"},{"issue":"3","key":"9662_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.drudis.2018.01.013","volume":"23","author":"W Li","year":"2018","unstructured":"Li W, Pang IH, Pacheco MTF, Tian H (2018) Ligandomics: a paradigm shift in biological drug discovery. Drug Discov Today 23(3):636\u2013643. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.013","journal-title":"Drug Discov Today"},{"issue":"10","key":"9662_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","volume":"22","author":"S Sau","year":"2017","unstructured":"Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK (2017) Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discov Today 22(10):1547\u20131556. https:\/\/doi.org\/10.1016\/j.drudis.2017.05.011","journal-title":"Drug Discov Today"},{"issue":"3","key":"9662_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/pbc.20931","volume":"48","author":"JC de Aguirre Neto","year":"2007","unstructured":"de Aguirre Neto JC, Antoneli CB, Ribeiro KB, Castilho MS, Novaes PE, Chojniak MM et al (2007) Retinoblastoma in children older than 5 years of age. Pediatr Blood Cancer 48(3):292\u2013295. https:\/\/doi.org\/10.1002\/pbc.20931","journal-title":"Pediatr Blood Cancer"},{"key":"9662_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/OPTH.S80049","volume":"9","author":"VS Dedania","year":"2015","unstructured":"Dedania VS, Bakri SJ (2015) Current perspectives on ranibizumab. Clin Ophthalmol 9:533\u2013542. https:\/\/doi.org\/10.2147\/OPTH.S80049","journal-title":"Clin Ophthalmol"},{"key":"9662_CR50","unstructured":"Drug_Information. Lucentis prescribing information by U.S. Food and Drug Administration at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/125156lbl.pdf"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-019-09662-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-019-09662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-019-09662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T01:38:59Z","timestamp":1720921139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-019-09662-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["9662"],"URL":"https:\/\/doi.org\/10.1007\/s10456-019-09662-4","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"7 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.E.L, H.T. and W.L. are shareholders of Everglades Biopharma, LLC and\/or LigandomicsRx, LLC. M.E.L., W.W. and W.L. are inventors of pending patents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}